Does the media prefer SOPH or OCUL?

In the previous week, Ocular Therapeutix had 3 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 12 mentions for Ocular Therapeutix and 9 mentions for SOPHiA GENETICS. Ocular Therapeutix's average media sentiment score of 0.65 beat SOPHiA GENETICS's score of 0.27 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MESO or SOPH?

SOPHiA GENETICS has a consensus target price of $9.00, indicating a potential upside of 58.73%. Given SOPHiA GENETICS's higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 SOPHiA GENETICS 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media favor MESO or SOPH?

In the previous week, SOPHiA GENETICS had 6 more articles in the media than Mesoblast. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 3 mentions for Mesoblast. SOPHiA GENETICS's average media sentiment score of 0.27 beat Mesoblast's score of 0.00 indicating that SOPHiA GENETICS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SOPHiA GENETICS 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TYRA or SOPH?

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 4 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.66 beat SOPHiA GENETICS's score of 0.27 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SOPHiA GENETICS 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SOPH or BCAX?

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Bicara Therapeutics. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.22 beat SOPHiA GENETICS's score of 0.27 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SOPHiA GENETICS (SOPH) Competitors

$5.67 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.66 -0.01 (-0.18%)

As of 07/31/2026 07:34 PM Eastern

Compare

SOPH vs. OCUL, MESO, LKFT, TYRA, and BCAX

Should you buy SOPHiA GENETICS stock or one of its competitors? MarketBeat compares SOPHiA GENETICS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SOPHiA GENETICS include Ocular Therapeutix (OCUL), Mesoblast (MESO), Lakefront Biotherapeutics American Depositary Shares (LKFT), Tyra Biosciences (TYRA), and Bicara Therapeutics (BCAX).

How does SOPHiA GENETICS compare to Ocular Therapeutix?

SOPHiA GENETICS (NASDAQ:SOPH) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

SOPHiA GENETICS has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

In the previous week, Ocular Therapeutix had 3 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 12 mentions for Ocular Therapeutix and 9 mentions for SOPHiA GENETICS. Ocular Therapeutix's average media sentiment score of 0.65 beat SOPHiA GENETICS's score of 0.27 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

SOPHiA GENETICS has higher revenue and earnings than Ocular Therapeutix. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	6.16	-$79M	-$0.52	N/A
Ocular Therapeutix	$51.95M	34.44	-$265.94M	-$1.46	N/A

SOPHiA GENETICS presently has a consensus price target of $9.00, indicating a potential upside of 58.73%. Ocular Therapeutix has a consensus price target of $25.11, indicating a potential upside of 207.36%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71

SOPHiA GENETICS has a net margin of -44.48% compared to Ocular Therapeutix's net margin of -558.24%. SOPHiA GENETICS's return on equity of -62.74% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

SOPHiA GENETICS and Ocular Therapeutix tied by winning 8 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

SOPHiA GENETICS has a consensus target price of $9.00, indicating a potential upside of 58.73%. Given SOPHiA GENETICS's higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, SOPHiA GENETICS had 6 more articles in the media than Mesoblast. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 3 mentions for Mesoblast. SOPHiA GENETICS's average media sentiment score of 0.27 beat Mesoblast's score of 0.00 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SOPHiA GENETICS	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mesoblast has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Mesoblast's return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

SOPHiA GENETICS has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A
SOPHiA GENETICS	$77.27M	6.16	-$79M	-$0.52	N/A

Mesoblast has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Mesoblast beats SOPHiA GENETICS on 9 of the 17 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $34.33, indicating a potential upside of 26.18%. SOPHiA GENETICS has a consensus target price of $9.00, indicating a potential upside of 58.73%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than SOPHiA GENETICS. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.72	$363.05M	-$1.41	N/A
SOPHiA GENETICS	$77.27M	6.16	-$79M	-$0.52	N/A

In the previous week, SOPHiA GENETICS had 8 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 1 mentions for Lakefront Biotherapeutics American Depositary Shares. SOPHiA GENETICS's average media sentiment score of 0.27 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.00 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SOPHiA GENETICS	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

SOPHiA GENETICS beats Lakefront Biotherapeutics American Depositary Shares on 10 of the 17 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 4 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.66 beat SOPHiA GENETICS's score of 0.27 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
SOPHiA GENETICS	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tyra Biosciences presently has a consensus price target of $47.00, indicating a potential upside of 47.43%. SOPHiA GENETICS has a consensus price target of $9.00, indicating a potential upside of 58.73%. Given SOPHiA GENETICS's higher possible upside, analysts clearly believe SOPHiA GENETICS is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tyra Biosciences has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Tyra Biosciences has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Tyra Biosciences' return on equity of -42.66% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

SOPHiA GENETICS has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
SOPHiA GENETICS	$77.27M	6.16	-$79M	-$0.52	N/A

Summary

Tyra Biosciences and SOPHiA GENETICS tied by winning 8 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Bicara Therapeutics?

SOPHiA GENETICS (NASDAQ:SOPH) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Bicara Therapeutics. MarketBeat recorded 9 mentions for SOPHiA GENETICS and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.22 beat SOPHiA GENETICS's score of 0.27 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SOPHiA GENETICS presently has a consensus target price of $9.00, suggesting a potential upside of 58.73%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 11.71%. Given SOPHiA GENETICS's higher possible upside, equities analysts clearly believe SOPHiA GENETICS is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

SOPHiA GENETICS has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.81, meaning that its share price is 181% less volatile than the broader market.

SOPHiA GENETICS has higher revenue and earnings than Bicara Therapeutics. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	6.16	-$79M	-$0.52	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Bicara Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Bicara Therapeutics' return on equity of -35.89% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Summary

SOPHiA GENETICS and Bicara Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get SOPHiA GENETICS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOPH vs. The Competition

Export

Metric	SOPHiA GENETICS	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$475.66M	$1.35B	$6.85B	$12.42B
Dividend Yield	N/A	4.76%	2.59%	10.03%
P/E Ratio	-10.90	275.31	282.30	24.66
Price / Sales	6.16	59.32	563.12	75.93
Price / Cash	N/A	30.56	28.60	46.71
Price / Book	8.22	4.61	10.96	6.07
Net Income	-$79M	-$25.90M	$3.49B	$347.99M
7 Day Performance	0.35%	-0.49%	-0.64%	-0.44%
1 Month Performance	5.98%	-4.66%	-5.23%	-4.81%
1 Year Performance	79.43%	-19.83%	61.97%	18.61%

SOPHiA GENETICS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOPH SOPHiA GENETICS	3.2071 of 5 stars	$5.67 flat	$9.00 +58.7%	+79.4%	$475.66M	$77.27M	N/A	520	Upcoming Earnings
OCUL Ocular Therapeutix	2.7548 of 5 stars	$8.45 -2.2%	$25.11 +197.2%	-31.5%	$1.89B	$51.95M	N/A	230	Upcoming Earnings Gap Up
MESO Mesoblast	0.3351 of 5 stars	$14.45 -0.8%	N/A	-6.6%	$1.89B	$17.20M	N/A	80	Gap Up
LKFT Lakefront Biotherapeutics American Depositary Shares	1.7087 of 5 stars	$28.15 +0.1%	$34.33 +22.0%	-16.8%	$1.85B	$1.26B	N/A	1,310	Upcoming Earnings Gap Up
TYRA Tyra Biosciences	3.1442 of 5 stars	$30.88 -0.6%	$47.00 +52.2%	+207.4%	$1.85B	N/A	N/A	20	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SOPH) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SOPHiA GENETICS (SOPH) Competitors

SOPH vs. OCUL, MESO, LKFT, TYRA, and BCAX

How does SOPHiA GENETICS compare to Ocular Therapeutix?

Summary

How does SOPHiA GENETICS compare to Mesoblast?

Summary

How does SOPHiA GENETICS compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does SOPHiA GENETICS compare to Tyra Biosciences?

Summary

How does SOPHiA GENETICS compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH vs. The Competition

SOPHiA GENETICS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SOPHiA GENETICS (SOPH) Competitors

SOPH vs. OCUL, MESO, LKFT, TYRA, and BCAX

How does SOPHiA GENETICS compare to Ocular Therapeutix?

Which has more volatility and risk, SOPH or OCUL?

Does the media prefer SOPH or OCUL?

Which has better earnings & valuation, SOPH or OCUL?

Do analysts recommend SOPH or OCUL?

Is SOPH or OCUL more profitable?

Do insiders & institutionals believe in SOPH or OCUL?

Summary

How does SOPHiA GENETICS compare to Mesoblast?

Do analysts recommend MESO or SOPH?

Does the media favor MESO or SOPH?

Is MESO or SOPH more profitable?

Which has better valuation & earnings, MESO or SOPH?

Which has more risk & volatility, MESO or SOPH?

Do insiders and institutionals believe in MESO or SOPH?

Summary

How does SOPHiA GENETICS compare to Lakefront Biotherapeutics American Depositary Shares?

Which has more volatility & risk, LKFT or SOPH?

Do analysts rate LKFT or SOPH?

Which has higher earnings and valuation, LKFT or SOPH?

Does the media favor LKFT or SOPH?

Is LKFT or SOPH more profitable?

Do insiders & institutionals have more ownership in LKFT or SOPH?

Summary

How does SOPHiA GENETICS compare to Tyra Biosciences?

Does the media favor TYRA or SOPH?

Do analysts recommend TYRA or SOPH?

Do insiders & institutionals hold more shares of TYRA or SOPH?

Which has more risk & volatility, TYRA or SOPH?

Is TYRA or SOPH more profitable?

Which has better valuation and earnings, TYRA or SOPH?

Summary

How does SOPHiA GENETICS compare to Bicara Therapeutics?

Do insiders and institutionals hold more shares of SOPH or BCAX?

Does the media prefer SOPH or BCAX?

Do analysts recommend SOPH or BCAX?

Which has more risk and volatility, SOPH or BCAX?

Which has stronger valuation and earnings, SOPH or BCAX?

Is SOPH or BCAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH vs. The Competition

SOPHiA GENETICS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools